Clinical trialPhase 1Recruiting
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 25 March 2025
- Expected end
- 15 October 2027
- Enrollment
- 437 participants
- Sites
- 8
- Primary outcomes
- Number of participants with Adverse Events (AEs); Number of participants with Serious AEs (SAEs); Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of deaths
- Sponsor
- Industry
- Results posted
- No
- Last update
- 29 July 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.